Vanguard Capital Management
INMB icon

Vanguard Capital Management’s INmune Bio INMB Stock Holding History

Vanguard Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
706,424
+19,409
+3% +$26.9K ﹤0.01% 3566
2026
Q1 		$776K Buy
+687,015
New +$979K ﹤0.01% 3599

Other funds holding INMB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management's INMB Position: Q2 2026 in Review

Vanguard Capital Management increased its INmune Bio (INMB) stake by 2.8% in Q2 2026, buying an estimated $26.9K and bringing the position to 706,424 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

Vanguard Capital Management first reported a position in INMB in Q1 2026 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Vanguard Capital Management held 706,424 shares of INmune Bio worth $1.15M as of Q2 2026.
  • Vanguard Capital Management bought 19,409 INmune Bio shares in Q2 2026, an estimated $26.9K.
  • INmune Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3566 holding.
  • Vanguard Capital Management first reported a position in INmune Bio in Q1 2026 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.